Novo Nordisk (DB:NOVA) - Stock Price, News & Analysis

NOVA Stock Overview

NOVA fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	4/6
Past Performance	6/6
Financial Health	4/6
Dividends	3/6

Rewards

Trading at 6.7% below our estimate of its fair value

Earnings are forecast to grow 14.81% per year

Earnings grew by 50.7% over the past year

Risk Analysis

No risks detected for NOVA from our risk checks.

Novo Nordisk A/S Competitors

Merck KGaA

XTRA:MRK

€66.8b

Dermapharm Holding

XTRA:DMP

€1.8b

Eli Lilly

NYSE:LLY

US$677.1b

Johnson & Johnson

NYSE:JNJ

US$355.5b

Price History & Performance

Summary of all time highs, changes and price drops for Novo Nordisk
Historical stock prices
Current Share Price	kr.117.50
52 Week High	kr.127.00
52 Week Low	kr.67.50
Beta	0.20
1 Month Change	-3.69%
3 Month Change	21.64%
1 Year Change	53.59%
3 Year Change	291.67%
5 Year Change	451.64%
Change since IPO	4,095.68%

Recent updates

Shareholder Returns

	NOVA	DE Pharmaceuticals	DE Market
7D	1.3%	0.4%	-1.2%
1Y	53.6%	-29.0%	1.2%

Return vs Industry: NOVA exceeded the German Pharmaceuticals industry which returned -29% over the past year.

Return vs Market: NOVA exceeded the German Market which returned 1.2% over the past year.

Price Volatility

Is NOVA's price volatile compared to industry and market?
NOVA volatility
NOVA Average Weekly Movement	4.4%
Pharmaceuticals Industry Average Movement	7.0%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	9.8%
10% least volatile stocks in DE Market	2.5%

Stable Share Price: NOVA has not had significant price volatility in the past 3 months.

Volatility Over Time: NOVA's weekly volatility (4%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1923	63,845	Lars Jorgensen	www.novonordisk.com

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas.

Novo Nordisk A/S Fundamentals Summary

How do Novo Nordisk's earnings and revenue compare to its market cap?
NOVA fundamental statistics
Market cap	€526.20b
Earnings (TTM)	€11.22b
Revenue (TTM)	€31.13b

46.9x

P/E Ratio

16.9x

P/S Ratio

Is NOVA overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
NOVA income statement (TTM)
Revenue	kr.232.26b
Cost of Revenue	kr.35.77b
Gross Profit	kr.196.50b
Other Expenses	kr.112.81b
Earnings	kr.83.68b

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

May 02, 2024

Earnings per share (EPS)	18.76
Gross Margin	84.60%
Net Profit Margin	36.03%
Debt/Equity Ratio	20.0%

How did NOVA perform over the long term?

See historical performance and comparison

Dividends

1.1%

Current Dividend Yield

50%

Payout Ratio

NOVA Stock Overview

Rewards

Risk Analysis

Novo Nordisk A/S Competitors

XTRA:MRK

€66.8b

XTRA:DMP

€1.8b

NYSE:LLY

US$677.1b

NYSE:JNJ

US$355.5b

Price History & Performance

Recent News & Updates

Mankind Reportedly Joins Race for Healthium Medtech

Novo Nordisk A/S (CPSE:NOVO B) agreed to acquire Cardior Pharmaceuticals GmbH from EQT Life Sciences and others for €1.03 billion.

Novo Nordisk Announces Awiqli Recommends for Approval for the Treatment of Diabetes by the European Regulatory Authorities

Novo Nordisk Announces US Food and Drug Administration Approves Wegovy® Based on A Supplemental New Drug Application for the Indication of Reducing Risk of Major Dose Cardiovascular Events

Novo Nordisk A/S Proposes Final Dividend for the Year 2023

Novo Nordisk A/S (CPSE:NOVO B) announces an Equity Buyback for DKK 20,000 million worth of its shares.

Recent updates

Mankind Reportedly Joins Race for Healthium Medtech

Novo Nordisk A/S (CPSE:NOVO B) agreed to acquire Cardior Pharmaceuticals GmbH from EQT Life Sciences and others for €1.03 billion.

Novo Nordisk Announces Awiqli Recommends for Approval for the Treatment of Diabetes by the European Regulatory Authorities

Novo Nordisk Announces US Food and Drug Administration Approves Wegovy® Based on A Supplemental New Drug Application for the Indication of Reducing Risk of Major Dose Cardiovascular Events

Novo Nordisk A/S Proposes Final Dividend for the Year 2023

Novo Nordisk A/S (CPSE:NOVO B) announces an Equity Buyback for DKK 20,000 million worth of its shares.

Novo Nordisk A/S Announces Topline Results from the Combine 3 Phase 3A Trial of Once-Weekly IcoSema

Novo Nordisk A/S to Report First Half, 2024 Results on Aug 07, 2024

Novo Nordisk Revises Earnings Guidance for the Year 2023

Novo Nordisk to Stop the Once-Weekly Injectable Semaglutide Kidney Outcomes Trial, Flow, Based on Interim Analysis

Novo Nordisk A/S (CPSE:NOVO B) acquired Embark Biotech ApS for approximately €470 million.

Novo Nordisk A/S (CPSE:NOVO B) agreed to acquire Inversago Pharma Inc. from Genesys Capital Partners Inc., Accel-Rx, Tarnagulla Ventures Pty. Ltd., Fonds de solidarité FTQ, adMare BioInnovations and others for $1 billion.

Novo Nordisk A/S Provides Earnings Guidance for the Year 2023

Novo Nordisk A/S (CPSE:NOVO B) agreed to acquire a 64.4% stake in Biocorp Production (ENXTPA:ALCOR) for €99.1 million.

Novo Nordisk Enters into Exclusive Negotiations to Acquire A Controlling Stake in Bicorp, to Be Followed by A Tender Offer on All Remaining Shares

Novo Nordisk A/S Announces Headline Results from OASIS 1

Novo Nordisk A/S to Report Fiscal Year 2023 Results on Jan 31, 2024

Heartseed and Novo Nordisk A/S Announces First Patient Dosed in Clinical Study with HS-001 – A Cell Therapy Designed to Restore Heart Function in People with Advanced Heart Failure

Novo Nordisk A/S (CPSE:NOVO B) announces an Equity Buyback for DKK 28,000 million worth of its shares.

Novo Nordisk Announces FDA Approval of Label Update for Rybelsus® (Semaglutide) Allowing Use as a First-Line Option for Adults with Type 2 Diabetes

Novo Nordisk A/S to Report First Half, 2023 Results on Aug 10, 2023

Novo Nordisk Announces Headline Results from the ONWARDS 5 Phase 3A Trial with Once-Weekly Insulin Icodec in People with Type 2 Diabetes

Novo Nordisk A/S (CPSE:NOVO B) entered into a definitive agreement to acquire Forma Therapeutics Holdings, Inc. (NasdaqGM:FMTX) from RA Capital Management, L.P. and others for approximately $990 million

Novo Nordisk A/S (CPSE:NOVO B) entered into a definitive agreement to acquire Forma Therapeutics Holdings, Inc. (NasdaqGM:FMTX) from RA Capital Management, L.P. and others for approximately $990 million

Novo Nordisk A/S Successfully Completes Phase 2 Trial with Cagrisema in People with Type 2 Diabetes

Novo Nordisk A/S Revises Earnings Guidance for the Full Year of 2022

Novo Nordisk Achieves Primary Objectives of Onwards 3 and 4 Trials with Once-Weekly Insulin Icodec Demonstrating Superior Reduction in Hba1c Vs Insulin Degludec in Onwards 3

Novo Nordisk Achieves Primary Objectives of ONWARDS 1 and 6 Trials

Novo Nordisk A/S to Report Fiscal Year 2022 Results on Feb 01, 2023

Novo Nordisk Announces US Food and Drug Administration Approve A 2.0 Mg Dose of Ozempic®

Novo Nordisk A/S Announces Board Changes

Novo Nordisk A/S (CPSE:NOVO B) announces an Equity Buyback for DKK 22,000 million worth of its shares.

Novo Nordisk A/S Provides Earnings Guidance for the Year 2022

Novo Nordisk A/S Announces Settlement of Securities Lawsuit in Denmark